Theravance Inc. (THRX): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Theravance ( THRX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.5%. By the end of trading, Theravance fell $0.48 (-1.4%) to $34.50 on heavy volume. Throughout the day, 1,778,344 shares of Theravance exchanged hands as compared to its average daily volume of 909,700 shares. The stock ranged in price between $34.23-$35.46 after having opened the day at $35.13 as compared to the previous trading day's close of $34.98. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 43.4%, Celator Pharmaceuticals ( CPXX), down 13.5%, Ocera Therapeutics ( OCRX), down 13.1% and American Caresource Holdings ( ANCI), down 8.7%.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Theravance has a market cap of $4.0 billion and is part of the drugs industry. Shares are up 57.3% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Oramed Pharmaceuticals ( ORMP), up 49.0%, Amarin Corporation ( AMRN), up 25.5%, AVANIR Pharmaceuticals ( AVNR), up 19.7% and Ariad Pharmaceuticals ( ARIA), up 16.5% , were all gainers within the health care sector with Amgen ( AMGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Flagged As Strong On High Volume

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

The 10 Highest Dividend Health Care Stocks Are Not All Buys

5 Hated Stocks You Should Love This Earnings Season